ECKERT & ZIEGLER BG Seneffe, Belgium, January 5, 2015. Due to the ongoing economic and political crisis in Eastern Europe and unexpectedly difficult conditions in the Americas business, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG: BB) was not able to match the sales figures of the previous years in the last quarter of 2014.
According to preliminary figures for the financial year 2014, management assumes that sales will be merely on par with the previous year's level of EUR 28 million. Instead of achieving earnings before interest and taxes (EBIT) comparable to EBIT levels in previous years, it will likely only be possible to realize a loss of almost EUR 3 million due to poorer capacity utilization in production. The final figures will be released on March 26, 2015.
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry.
Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with subsidiaries throughout Europe, in the U.S., India and Brazil. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line. The company's products and equipment are intended for use by oncologists, radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 200 people. The company has been listed on the NYSE Euronext stock exchange since April 1997.
Contact:
Annica Witt
Investor Relations
Tel.: +32 (0) 64 520 808
ir@bebig.eu:
mailto:ir@bebig.eu
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Globenewswire
